Results 91 to 100 of about 106,721 (360)

Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation

open access: yesHepatology, 2020
Altered bile acid (BA) homeostasis is an intrinsic facet of cholestatic liver diseases, but clinical usefulness of plasma BA assessment in primary sclerosing cholangitis (PSC) remains understudied.
O. Mousa   +18 more
semanticscholar   +1 more source

Primary Sclerosing Cholangitis

open access: yesSurgical Clinics of North America, 1990
Primary sclerosing cholangitis is a rare disease of unknown etiology. Sclerosis of the bile ducts may actually be the final result of multiple factors such as autoimmune, bacterial, congenital, drug, or viral injury. The most commonly associated diseases are ulcerative colitis and chronic pancreatitis.
K D, Lillemoe, H A, Pitt, J L, Cameron
openaire   +2 more sources

Intrahepatic cholangiocarcinoma: review and update [PDF]

open access: yes, 2018
Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies that could develop at any level from the biliary tree. CCA is currently classified into intrahepatic (iCCA), perihilar and distal on the basis of its anatomical location.
Alvaro, Domenico   +7 more
core   +1 more source

Monocytes as Potential Mediators of Pathogen‐Induced T‐Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC)

open access: yesHepatology, 2020
T cells from patients with primary sclerosing cholangitis (PSC) show a prominent interleukin (IL)‐17 response upon stimulation with bacteria or fungi, yet the reasons for this dominant T‐helper 17 (Th17) response in PSC are not clear.
Lilly K. Kunzmann   +30 more
semanticscholar   +1 more source

Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities

open access: yesJournal of gastroenterology, 2020
Primary sclerosing cholangitis (PSC) is a progressive liver disease, histologically characterized by inflammation and fibrosis of the bile ducts, and clinically leading to multi-focal biliary strictures and with time cirrhosis and liver failure. Patients
M. Vesterhus, T. Karlsen
semanticscholar   +1 more source

Efficacy, safety, and relapse outcomes of MAPK inhibitors in pediatric Langerhans cell histiocytosis: A real‐world study

open access: yesInternational Journal of Cancer, EarlyView.
What's new? Mitogen‐activated protein kinase (MAPK) inhibitors are promising treatments for pediatric Langerhans cell histiocytosis (LCH), a rare heterogeneous neoplasm that often affects multiple organ systems. Which MAPK inhibitors are most effective against LCH remains uncertain.
Xue Tang   +5 more
wiley   +1 more source

Liver involvement in pediatric celiac disease [PDF]

open access: yes, 2015
Celiac disease (CD) is an intestinal inflammatory disease that manifests in genetically susceptible individuals when exposed to dietary gluten. It is a common chronic disorder, with a prevalence of 1% in Europe and North America.
Anania, Caterina   +4 more
core   +1 more source

Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis

open access: yesGut, 2019
Objective Patients with primary sclerosing cholangitis (PSC) were previously shown to display a bacterial gut dysbiosis but fungal microbiota has never been examined in these patients.
S. Lemoinne   +8 more
semanticscholar   +1 more source

Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities

open access: yesHepatology, 2020
Lifetime risk of biliary tract cancer (BTC) in primary sclerosing cholangitis (PSC) may exceed 20%, and BTC is currently the leading cause of death in patients with PSC.
B. Goeppert   +35 more
semanticscholar   +1 more source

Multicenter Validation Study of the Clinical Diagnostic Criteria for IgG4‐Related Sclerosing Cholangitis 2020 in Japan

open access: yesJournal of Hepato-Biliary-Pancreatic Sciences, EarlyView.
ABSTRACT Background The diagnostic performance of clinical diagnostic criteria for IgG4‐related sclerosing cholangitis 2020 (IgG4‐SC2020) has not been fully validated since its proposal as a revision of the 2012 criteria (IgG4‐SC2012). Methods We conducted a multicenter validation study to evaluate the diagnostic performance of IgG4‐SC2020 using ...
Itaru Naitoh   +60 more
wiley   +1 more source

Home - About - Disclaimer - Privacy